127 related articles for article (PubMed ID: 38038422)
1. The association of genetic factors with serum calretinin levels in asbestos-related diseases.
Zupanc C; Franko A; Strbac D; Kovac V; Dolzan V; Goricar K
Radiol Oncol; 2023 Dec; 57(4):473-486. PubMed ID: 38038422
[TBL] [Abstract][Full Text] [Related]
2. Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.
Zupanc C; Franko A; Štrbac D; Kovač V; Dolžan V; Goričar K
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203360
[TBL] [Abstract][Full Text] [Related]
3. The role of polymorphisms in glutathione-related genes in asbestos-related diseases.
Franko A; Goricar K; Dodic Fikfak M; Kovac V; Dolzan V
Radiol Oncol; 2021 Jan; 55(2):179-186. PubMed ID: 33544514
[TBL] [Abstract][Full Text] [Related]
4. Serum Calretinin as a Biomarker in Malignant Mesothelioma.
Zupanc C; Franko A; Štrbac D; Dodič Fikfak M; Kovač V; Dolžan V; Goričar K
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768395
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A
Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018
[TBL] [Abstract][Full Text] [Related]
6. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
7. Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
Blum W; Pecze L; Rodriguez JW; Steinauer M; Schwaller B
BMC Cancer; 2018 Apr; 18(1):475. PubMed ID: 29699512
[TBL] [Abstract][Full Text] [Related]
8. The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma.
Piber P; Vavpetic N; Goricar K; Dolzan V; Kovac V; Franko A
Radiol Oncol; 2020 Oct; 54(4):429-436. PubMed ID: 33085641
[TBL] [Abstract][Full Text] [Related]
9. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
[TBL] [Abstract][Full Text] [Related]
10. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
[TBL] [Abstract][Full Text] [Related]
11. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
[TBL] [Abstract][Full Text] [Related]
12. Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors.
Helmig S; Belwe A; Schneider J
J Investig Med; 2009 Jun; 57(5):655-61. PubMed ID: 19349911
[TBL] [Abstract][Full Text] [Related]
13. Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2
Blum W; Henzi T; Châtel-Soulet HE; Pecze L; Rodriguez JW; Vrugt B; Schwaller B
Biomark Res; 2018; 6():19. PubMed ID: 29928505
[TBL] [Abstract][Full Text] [Related]
14. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
15. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
Kresoja-Rakic J; Kapaklikaya E; Ziltener G; Dalcher D; Santoro R; Christensen BC; Johnson KC; Schwaller B; Weder W; Stahel RA; Felley-Bosco E
Oncotarget; 2016 Apr; 7(16):21272-86. PubMed ID: 26848772
[TBL] [Abstract][Full Text] [Related]
16. Telomere length and
Mervic A; Goricar K; Blagus T; Franko A; Trebusak-Podkrajsek K; Fikfak MD; Dolzan V; Kovac V
Radiol Oncol; 2024 Mar; 58(1):87-98. PubMed ID: 38378028
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.
Franko A; Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V
J Med Biochem; 2020 Jan; 39(1):91-99. PubMed ID: 32549782
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
19. Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
Lehnert M; Weber DG; Taeger D; Raiko I; Kollmeier J; Stephan-Falkenau S; Brüning T; Johnen G;
BMC Res Notes; 2020 Jul; 13(1):359. PubMed ID: 32727552
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
